User Comments Most Liked Latest
Login to join the conversation.
Reddit Mentions Today Week Month
BEAT / HEARTBEAM: 5X Play or Total Rug Pull? $BEAT — +500% Runner or -70% Slam? Probably the craziest FDA risk/reward setup out there right now.
BEAT / HEARTBEAM: 5X Play or Total Rug Pull? $BEAT — +500% Runner or -70% Slam? Probably the craziest FDA risk/reward setup out there right now.
BEAT HEARTBEAM STOCK : 5X Play or Rug Pull , $BEAT STOCK +500% Runner or -70% Disaster ? The Wildest FDA Risk/Reward
HeartBeam,Inc- BEAT 🚨
HeartBeam,Inc- BEAT 🚨
HeartBeam,Inc- BEAT 🚨 HeartBeam Inc. practically already has an agreement and a pre-order for the new product HeartBeam AIMIGo™, but for now this will all be officially registered after final approval from the FDA, and now they refer to a commercial secret. In its report, Roth Capital confirmed the target …
[BEEEEEEAT](http://aimytrade.io/ticker/BEAT)
Time to beat it. [BEAT](http://aimytrade.io/ticker/BEAT)
BEAT 🚀🚀🚀
Heartbreak , inc . BEAT 🌏 The crazy volume only suggests that someone from the institution has entered into a position. And most likely has an idea of a positive outcome with an appeal.
Is it? [BEAT](https://aimytrade.io/ticker/BEAT)
[BEAT BEAT BEAT](https://aimytrade.io/ticker/BEAT)
Heartbeam (BEAT) I think the reaction to NSE letter is overblown. Short volume spiked on Friday. Might be ripe for a lil squeeze soon.
$BEAT - Strong Buy 🚀
Beat. it. [BEAT](http://aimytrade.io/ticker/BEAT)
PRPH, SGBX, and BEAT
still BEAT
BEAT 🟢 -Volume 100 mln🚀
HeartBeam,Inc -BEAT 🚀🚀🚀
BEAT JP Morgan just bought in last week
This comment section will be COOK NFE BEAT
I am interested, but the standard 3D has been approved since dec 2024 with no move to market. The NSE issue with the 12 wire software package may be a monkey wrench because it seems it is the lynch pin to the whole market strategy. If the FDA determines they …
BEAT 💵💵💵
&BEAT.-Strategy + Resources + Connections🚨 Richard Ferrari is the co-founder of a venture capital firm (Venture Capital), providing access to capital raising experience and an understanding of how to scale medical startups. • Having commercial sales and marketing veterans on the board (e.g., Ken Nelson) increases the chances that, if …
Beat it beat iiit [BEAT](https://aimytrade.io/ticker/beat)
BEAT 🚀🚀🚀
[BEAT IT BEAT IT](https://aimytrade.io/ticker/BEAT)
🟢Heartbeam -BEAT
💎BEAT - Board of Directors .Mr. Ferrari Richard Ferrari has been the Executive Chairman of the Board of Directors of HeartBeam since 2021 and a board member since 2019. He has over 40 years of experience in the medical device industry, serving as the CEO of several startups and as …
$BEAT 🍺 BEAT's move looks good
$BEAT 🚀🍺
BEAT What do you guys think beat will do tomorrow?
@BEAT - News
$BEAT and $COOK 🚀🚀💲
@BEAT - News The financing issue will be resolved favorably, as the main institutional holder is not interested in diluting the shares. A private placement is possible, which will not affect the total number of shares outstanding.
Anyone in BEAT?
$BEAT MONDAY 🚀
$BEAT MONDAY 🚀 Buy low
I’m holding BEAT and $PRPH for monday
$BEAT MONDAY 🚀🚀
$BEAT -Strome investment management
Heart Beam $BEAT moon soon🚀
Heart Beam $BEAT moon soon🚀 BEAT Could Continue Going Up ✅ 1. The recent news removes a major regulatory risk The company published an update on its FDA regulatory pathway, clarifying that: • The FDA did not reject the product. • The process remains active and on track. • HeartBeam …
$BEAT
BEAT
$BEAT MONDAY 🚀🚀
$BEAT 🚀🚀
HeartBeam,Inc🤝FDA 🟢 The FDA itself is interested in HeartBeam's work and approval of its application, especially since it has already approved earlier ones. HeartBeam (BEAT) will be launching its previously approved product, the HeartBeam AIMIGo™ System, in the coming weeks.
BEAT (HeartBeam Inc.) – After the FDA NSE decision, the company dropped a clear regulatory plan. High risk, high reward setup worth watching (Not Financial Advice)
$BEAT
[BEAT IT BEAAAT IT](http://aimytrade.io/ticker/BEAT)
Last chance to get in. [BEAT IT](http://aimytrade.io/ticker/BEAT)
BEAT, 🎇
$BEAT had a nice dip it’s starting to go back up get in while you can.
$BEAT
Beat my meat [BEAT](https://aimytrade.io/ticker/BEAT)
Time to beat it. [BEAT](https://aimytrade.io/ticker/BEAT)
BEAT 🚀🚀🚀
$BEAT
TIME TO [BEAT](http://aimytrade.io/ticker/BEAT) THE MARKET
[Beats me](http://aimytrade.io/ticker/BEAT)
I’m all in on BEAT right now with 8000 shares
BEAT
Im in BEAT
Tons of volume and BEAT is dumping strange market...lol
$BEAT Pretty solid choice at the moment, given the FDA cooperation.
SGBX SMX BEAT
BEAT
BEAT
BEAT 🟢5️⃣💰🚀🚀🚀
BEAT is looking juicy
got a little bit of BEAT and BIYA this am
TIME TO BEAT [BEAT](http://aimytrade.io/ticker/BEAT)
BEAT MEAT [BEAT](http://aimytrade.io/ticker/BEAT)
BEAT!!
On BEAT.
BEAT
DVLT for long, MBOT, and BEAT
BEAT gaining volume
Anyone doing BEAT?
What’s up with BEAT I like the volume. Might jump in.
buying more BEAT
Most probably BEAT , NFE
HeartBeam (BEAT)- APPLE 🍏 Richa Gujarati✅ Richa Gujarati has been Senior Vice President of Product at HeartBeam since 2023. Previously, she led Health Products for Apple Watch ⌚️ at Apple, focusing on sensors, apps, and healthcare partnerships. Additional Experts Mohammad Shokoohi-Yekta worked at Apple in data science before joining HeartBeam …
BEAT might be one to watch...new news Fda working with them... https://finance.yahoo.com/news/heartbeam-beat-partners-heartnexus-deliver-190000661.html
HeartBeam inc, Nasdaq: BEAT. 🤝FDA ✅ https://ir.heartbeam.com/news-events/press-releases/detail/106/heartbeam-provides-update-on-regulatory-path-following-fda
BEAT 🟢 will test $2 today
BEAT- HeartBeam,Inc🟢🟢🟢🟢🟢🟢🟢🟢🟢🟢🟢🟢🟢🟢
HeartBeam, Inc-BEAT 🚀🚀🚀
HeartBeam, Inc - BEAT
BEAT
BEAT Moving upwards quickly, my Posts are getting removed, really believe this stock is going to be a mover. Expecting good results next quarter and i feel they can make the modifications needed to get their latest product approved by the fda.
NFE and BEAT
BEAT - Lots of room for reversal. Over 94% accuracy of the test. Huge positive news just came out on Wednesday’s after hours. 😛
HeartBeam,Inc🟢 Analysts' target price forecasts for HeartBeam Inc. (BEAT) in 2025 have significantly increased as the company progressed and released quarterly reports. At the beginning of the year, analysts' target price was lower, around $4.00, but by mid-year and following the second-quarter 2025 earnings call, analysts from Benchmark and other …
[BEAT THA MEAT](http://aimytrade.io/ticker/BEAT)
BEAT 🟢🤝FDA "We have engaged in good faith with the agency over a period of two years and have had extremely positive interactions. Together with the agency, we resolved the vast majority of open questions," said Robert Eno, Chief Executive Officer of HeartBeam. The company maintains that its VALID-ECG clinical …
BEAT - 🙈
$BEAT FOR THE WIN! We passed the moon 20 cents ago
$BEAT is ripping
BEAT tomorow TOO the moon
BEAT good news! Free money under a dollar
BEAT✅🔥News https://finance.yahoo.com/news/heartbeam-provides-regulatory-path-following-213200472.html
BEAT 🟢Boom https://ir.heartbeam.com/news-events/press-releases/detail/106/heartbeam-provides-update-on-regulatory-path-following-fda
[BEAT THA MEAT](https://aimytrade.io/ticker/BEAT)
BYND BEAT
BEAT 🟢🟢🟢Strong Buy✅✅✅
BEAT 💰Strong Buy✅✅✅
HeartBeam. Inc , BEAT 💰🚀🚀🚀
BEAT 🚀Breakthrough
BEAT - HeartBeam (BEAT) Receives FDA Feedback ;Roth Maintains Optimistic Outlook HeartBeam (BEAT, Financial) maintains a Buy rating from Roth Capital with a price target of 4 $
BEAT 🚀🚀🚀
BEAT 🟢🟢🟢TipRanks⚫️🟠 https://www.tipranks.com/news/the-fly/roth-sees-potential-fda-clearance-for-heartbeam-despite-letter-thefly
BEAT.In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …
In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …
In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …
In the short term, positive developments for BEAT shares could arise from: • Promotion and potential commercial launch of the already approved 3D ECG system, which the company views as an alternative revenue source. • Confidence in clinical data and scientific potential, supporting hopes for a successful FDA approval. • …
BEAT -Roth Capital 🟢🟢🟢 Roth Capital analysts' key arguments for continued growth in HeartBeam (BEAT) stock include: • Significant potential for 3D ECG technology for remote cardiac monitoring, which addresses a critical healthcare need. • Expected expansion of medical applications for the software following feedback from the FDA, despite the …
BEAT 🟢 Benchmark agency Benchmark justifies its $8 target price for HeartBeam (BEAT) primarily based on the company's progress toward FDA 510(k) clearance for its innovative cardiac monitoring technology. They emphasize the potential for strong revenue growth from the commercial launch of HeartBeam's 3D vector ECG plattorm in preventive and …
HeartBeam,Inc - (ticker BEAT)🟢 HeartBeam is a medical technology company focused on advanced cardiac monitoring, including a portable 3D ECG technology that has received FDA clearance for arrhythmia assessment. HeartBeam's technology is distinct and focuses on 12-lead ECG synthesis and advanced cardiac diagnostics, aiming to transform heart monitoring outside medical …
BEAT 🟢🟢🟢🟢🟢🟢🟢🟢🟢🟢
BEAT 🚀🚀🚀💎💎💎
BEAT ✅ In the zone of strong oversold
BEAT 🟢🟢🟢🟢🟢
$BEAT
$BEAT
$BEAT Stumbled across HeartBeam ($BEAT) recently and wanted to throw it out here for discussion because the concept caught my eye. Not financial advice, obviously — just sharing research and seeing what others think. HeartBeam is working on tech aimed at improving how cardiac events are detected outside the hospital …
$BEAT Stumbled across HeartBeam ($BEAT) recently and wanted to throw it out here for discussion because the concept caught my eye. HeartBeam is working on tech aimed at improving how cardiac events are detected outside the hospital setting. What makes them stand out (at least to me) is that they’re …
BEAT ✅ Volumes increased 10-fold, from the monthly average to 2 million shares, which indicates that interest in shares has grown.
BEAT ✅
BEAT -HeartBeam,Inc 🟢 Roth Capital keeps a Buy rating on HeartBeam (BEAT) with a $4✅ price target after the company received a ⚠️“not substantially equivalent” ⚠️letter from the FDA regarding its 510(k) application for its 12-lead electrocardiogram synthesis software. Roth believes the FDA may want the company to use a …
BEAT HeartBeam (BEAT, Financial) continues to hold a Buy rating from Roth Capital with a set price target of $4. The company recently received a "not substantially equivalent" letter from the FDA concerning its 510(k) application for its 12-lead electrocardiogram synthesis software. This feedback suggests that the FDA might be …
BEAT 🟢🟢🟢🟢🟢🚀🚀🚀🟢🟢🟢 5️⃣💰💰💰
If you're talking about $BEAT I was holding this stock for months, and it got beaten to -60% after the bad news from the FDA dropped yesterday.
BEAT🚀
BEAT BEAT 🎇
HeartBeam,Inc. (:-BEAT )
BEAT 🟢🟢🟢🟢🟢
BEAT 🚀🚀🚀
BEAT 🚀
BEAT
BEAT (HeartBeam) Anyone saw this stock falling down after NSE letter they Got from FDA? Roth Capital sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said. HeartBeam is …
BEAT 🟢 HeartBeam (BEAT) Receives FDA Feedback; Roth Maintains Optimistic Outlook BEAT guru GuruFocus News 21.11.2025, 23:25:56 Aa Key Takeaways: • HeartBeam (BEAT, Financial) maintains a Buy rating from Roth Capital with a price target of $4. • The FDA has issued a "not substantially equivalent" letter regarding HeartBeam's 12-lead …
Booooom 🚨BEAT 🟢
BEAT 💵🔥
BEAT 🟢Price recovery at $1.8
BEAT 💎Today - 1,08 $🚀🚀🚀
BEAT 🔥🔥🔥BEAT 🚀🚀🚀BEAT ✅✅✅
BEAT 🚀🚀🚀
BEAT 🟢🚀🚀🚀Right now🚀🚀🚀
BEAT BEAT BEAT 🚀🚀🚀 Strongly oversold on Minor Information. Rebound by 30-40% until a full price recovery.
Anyone watching BEAT? Volume building
$BULL SHORT SQUEEZE SETTING UP TOMMOROW EARNINGS BEAT 🚀🚀🚀🚀
NVDA BEAT EARNINGS MFFFFSSS
BREAKING NEWS: NVDA DIDN’T BEAT THE EARNING BY $1
Related News
No related news found for this ticker.
Badges / Notes
- No notable badges.
Total Off-Exchange Volume: 782233
Values over 50% Short often indicate hidden bearish pressure from institutions.
🏆 Master Buzz Score: 1/15
Capitol Trades
| Date | Politician | Amount |
|---|---|---|
| No recent trades found. | ||
Insider Trades
| Date | Insider | Value |
|---|---|---|
| No recent trades found. | ||
Institutional Holdings (Whales)
| Institution | Shares | Value | % Held | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 1,118,392 | $861161 | 0.0325% | Sep 30, 2025 |
| Smith Salley Wealth Management | 367,647 | $283088 | 0.0107% | Sep 30, 2025 |
| Geode Capital Management, LLC | 293,598 | $226070 | 0.0085% | Sep 30, 2025 |
| UBS Group AG | 192,553 | $148265 | 0.0056% | Sep 30, 2025 |
| Kestra Private Wealth Services, LLC | 175,989 | $135511 | 0.0051% | Sep 30, 2025 |
| Ritholtz Wealth Management | 139,182 | $107170 | 0.0040% | Sep 30, 2025 |
| O'Shaughnessy Asset Management LLC | 139,182 | $107170 | 0.0040% | Sep 30, 2025 |
| Stifel Financial Corporation | 100,000 | $76999 | 0.0029% | Sep 30, 2025 |
| Blackrock Inc. | 90,044 | $69333 | 0.0026% | Sep 30, 2025 |
| Raymond James Financial, Inc. | 88,050 | $67798 | 0.0026% | Sep 30, 2025 |
No comments yet. Be the first!